Bimekizumab: Dual IL-17A/IL-17F inhibition in SpA

Bimekizumab has shown positive efficacy and safety results in the BE COMPLETE and BE OPTIMAL phase 3 psoriatic arthritis trials.

Joseph Merola talks about the BE COMPLETE and BE OPTIMAL trials, which showed that the dual IL-17A/IL-17F inhibitor bimekizumab is a promising treatment option for psoriatic arthritis patients with and without prior exposure to TNF inhibitors.

Philippe Carron comments on the findings from the BE COMPLETE and BE OPTIMAL studies, and discusses how bimekizumab may impact the psoriatic arthritis treatment landscape if approved by the regulatory authorities.

The results of two phase 3 studies suggest that dual inhibition of IL-17A and IL-17F with bimekizumab may represent a promising treatment option for nonradiographic axial spondyloarthritis and ankylosing spondylitis.

Désirée van der Heijde outlines the findings of two phase 3 trials demonstrating that bimekizumab may be beneficial for patients with nonradiographic axial spondyloarthritis or ankylosing spondylitis.

Fabian Proft discusses the potential impact of bimekizumab on the treatment of radiographic and nonradiographic axial spondyloarthritis in light of findings from the BE MOBILE 1 and 2 trials.

Follow-up results from the BE ACTIVE and BE AGILE phase 2b trials show that the efficacy and safety profiles of bimekizumab are maintained for up to 3 years in patients with psoriatic arthritis or ankylosing spondylitis.

Bimekizumab shows sustained benefit in the treatment of patients with ankylosing spondylitis, 48-week data show.

Bimekizumab may offer a new therapeutic option for patients with ankylosing spondylitis, findings from the BE AGILE study indicate.